NEXT-GENERATION AI
FOR CANCER DRUG
TARGET DISCOVERY

More about us

ABOUT US

In MNM Bioscience, we combine next-generation AI with the most advanced genomic approaches (Whole-genome and Multiomics data) to save the lives of cancer patients through predictive modeling and drug target identification.

For that purpose, we developed CARTHERai and TARGET DISCOVERY PLATFORM.

TECHNOLOGY

We harvest the power of whole-genome and MultiOmics data through proprietary AI solutions for
therapy response predictions and drug target identification

CDx DEVELOPMENT PIPELINE

Portfolio of predictive and prognostic models ready for licensing.
We invite investors and biopharma companies to collaborative partnerships in CDx development.

OUR PUBLICATIONS

Pawel Zawadzki,

Co-founder and CEO

The idea for MutationsNoMore (MNM) was born while I was at Oxford University, where I understood that a new “dictionary” for interpreting a tumor’s mutation language is needed. 
Over the past three years, we have built technology translating different mutation types; from single point mutations, structural changes to patterns of mutations into biological insights.
Unfortunately, we have discovered that there is no appropriate AI technology to process this new type of data, so we have built a new AI framework – our most valuable asset.  
I am proud that MNM’s newly discovered insights are already being validated in clinics in the form of algorithms predicting response to cancer drugs, and new drug targets we discovered are ready for validation.

Any questions?

Contact us

Contact page